DSIP
Sleep & RecoveryResearch-GradeLast reviewed: September 20, 2026
Quick Facts
- What it is
- Delta Sleep-Inducing Peptide — a naturally occurring neuropeptide studied for sleep regulation, stress resistance, and pain, described as a sleep modulator rather than a direct sedative.
- How it's taken
- Subcutaneous injection, usually at bedtime (intranasal also used)
- Half-life
- Short plasma half-life; biological effects persist far longer
- Typical research dose
- 100–200 mcg subcutaneously at bedtime, in 5–7 day cycles
- Research status
- Not FDA-approved — research use only; FDA has flagged potential immunogenicity.
On this page
- 1.Where to source DSIP
- 2.What is DSIP?
- 3.How does DSIP work?
- 4.What is DSIP used for?
- 5.How long does DSIP take to work?
- 6.How is DSIP dosed?
- 7.How is DSIP administered?
- 8.What does DSIP stack well with?
- 9.What are the side effects of DSIP?
- 10.Does DSIP interact with other drugs?
- 11.How should DSIP be stored?
- 12.What are the limitations of DSIP research?
- 13.DSIP FAQ
- 14.References
- 15.Published Studies
- 16.In the News
Where to source DSIP
DSIP is not FDA-approved and is sold by specialty research peptide vendors. Quality varies and the FDA has flagged immunogenicity concerns — third-party testing is especially important. The vendors highlighted below have been vetted — including nasal and pre-blended (Asleep) format options.
ILS Laboratories · batch COAs
Kovera, Chromate and BioRegen · certificates checked at each lab
Batch-traceable COAs · cold-chain shipping
Also stocking DSIP
Peptides.gg, Royal Peptides, Vital Core Research, Ameano Peptides — each carries a current price row for this compound.
What is DSIP?
DSIP (Delta Sleep-Inducing Peptide, also called Emideltide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, single-letter code WAGGDASGE) first isolated in 1977 from the cerebral venous blood of rabbits exhibiting deep slow-wave (delta) sleep. It is found in human brain, plasma, and breast milk. Unlike typical peptides, DSIP can cross the blood-brain barrier and is partially absorbed via the gut. Despite its name and decades of research, DSIP's role as a primary sleep-regulating compound remains uncertain — modern research describes it more accurately as a sleep-modulating substance that improves disturbed sleep without significantly affecting healthy sleepers. It also has documented anti-stress, antioxidant, and possible neuroprotective effects. New to peptide research? Start with the basics
Reported benefits:
- May improve slow-wave (delta) sleep depth in disturbed sleepers
- Anti-stress: blocks corticotropin release, reduces CRF-induced corticosterone
- Antioxidant effects in animal models
- Possible neuroprotection in stroke models
- Antinociceptive (pain-reducing) effects in animal research
- No sedation in healthy individuals — modulates rather than forces sleep
Common research dose: Typical research dose: 100–200 mcg subcutaneously at bedtime. Reported cycle: 5–7 days, then a break.
Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.
How does DSIP work?
DSIP's mechanism remains incompletely characterized after 50 years of research. It appears to be a sleep-modulating substance (not direct sedative) — most effective in disturbed sleepers, minimal effect on healthy sleepers. Possible targets include NMDA receptors, GABA-A and glycine receptor sites, and α1-adrenergic receptors. It also has documented anti-stress effects (blocks CRF-induced corticosterone), antioxidant activity, and hormonal modulation (LH, GH, somatostatin). The breadth of effects without a clearly identified receptor is part of why DSIP is described as 'a still unresolved riddle'.
- Sleep Modulation [1]. DSIP acts more as a sleep-promoting substance than a direct sedative. Its activity is greatest in subjects with disturbed sleep, with minimal effect on healthy sleepers. A dose given during the day may improve sleep on subsequent nights — suggesting downstream regulatory effects rather than acute sedation.
- Receptor Mechanism Unclear. DSIP's molecular targets are incompletely characterized. Its effects may involve NMDA receptors, GABA-A and glycine receptor sites, and α1-adrenergic receptors. The mechanism by which it modulates sleep architecture is not definitively established.
- Stress Axis Modulation [2]. DSIP decreases basal corticotropin levels and blocks ACTH release. It reduces CRF-induced corticosterone release. This anti-stress effect may be primary, with sleep effects emerging downstream of stress reduction.
- Antioxidant Activity [3]. DSIP has been shown to enhance the efficiency of oxidative phosphorylation in rat mitochondria and activate natural antioxidant mechanisms. A 2011 study concluded a 'strong antioxidant effect' in rat models.
- Hormonal and Endocrine Effects. DSIP has been observed to stimulate luteinizing hormone (LH) release, stimulate somatotrophin (GH) secretion via GHRH-like effect, and inhibit somatostatin secretion. It also normalizes blood pressure and myocardial contraction in some models.
What is DSIP used for?
DSIP's research evidence base spans disturbed sleep (most established application in early human research), stress and anxiolytic effects (Russian research), cerebral ischemia/stroke models, antinociception (pain reduction), and geroprotection (mouse study showing lifespan extension and reduced tumor incidence). Most research is from the 1970s-1990s with limited modern human clinical trials. The mechanism remains incompletely characterized.
- Disturbed Sleep [4]. Schneider-Helmert et al. 1981 gave IV DSIP to 6 healthy volunteers (not chronic insomnia patients) in a double-blind crossover design; the paper's own abstract does not state randomization. Total sleep time increased 59% within 130 minutes versus placebo, with shorter sleep onset and better efficiency on subsequent nights. This is Human Observational evidence — a controlled, blinded crossover study, not confirmed as randomized, and in healthy rather than insomnia-affected subjects.
- Stress and Anxiolytic Effects [2]. Russian research has explored DSIP's role in stress resistance. The peptide blocks corticotropin and reduces stress hormones in animal models, and has been associated with anxiolytic effects in rodent paradigms.
- Cerebral Ischemia and Stroke [5]. Multiple Russian studies show DSIP reduces ischemic damage in stroke models. A 2021 MDPI study showed intranasal DSIP improved motor function recovery in rats after focal stroke.
- Antinociception (Pain Reduction) [6]. Centrally administered DSIP shows antinociceptive (pain-reducing) effects in animal pain models. Mechanism unclear.
- Geroprotection. A long-term mouse study showed DSIP injections decreased spontaneous tumor incidence 2.6-fold, slowed age-related estrous decline, decreased chromosome aberrations 22.6%, and increased maximum lifespan 24.1%. Limited replication and species generalizability.
How long does DSIP take to work?
DSIP effects develop on multiple timescales. Acute effects on disturbed sleep may appear from the first dose, though the most consistent reports describe improved sleep over the following 1–7 days. Some research suggests DSIP given during the day produces improved sleep on subsequent nights — implying delayed/downstream effects rather than direct sedation. Long-term effects (stress resilience, antioxidant) build over weeks. Plasma half-life is short, but biological effects persist longer than pharmacokinetics would predict.
Acute effects on disturbed sleep may appear from the first dose, though the most consistent reports describe improved sleep over the following 1–7 days. Some research suggests DSIP given during the day produces improved sleep on subsequent nights — implying delayed/downstream effects rather than direct sedation. Long-term effects (stress resilience, antioxidant) build over weeks. The peptide's plasma half-life is short, but biological effects persist much longer than pharmacokinetics would predict — a recurring pattern for peptides that work through gene expression rather than direct receptor agonism.
How is DSIP dosed?
There is no standardized human dosing protocol for DSIP. The figures below are split into what the cited literature administered and, separately, community-reported practice.
Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.
Need to calculate a dose?
Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.
Open CalculatorWhat the cited literature administered
Human study (acute IV dosing) [4]. Schneider-Helmert et al. (Int J Clin Pharmacol Ther Toxicol, 1981, PMID 6895513) gave DSIP to 6 healthy volunteers (4 male, 2 female) as a slow intravenous infusion at 25 nmol/kg in the morning, in a double-blind crossover design the paper’s own abstract does not describe as randomized. Using DSIP’s molecular weight, 25 nmol/kg works out to roughly 21 mcg/kg — for a 70 kg adult, on the order of 1.5 mg given as a single IV infusion, not a subcutaneous injection, and not a daily or repeated-dose regimen. This is Human Observational evidence, not a randomized controlled trial by the paper’s own description.
Adverse events at that dose [4]. The paper’s own abstract reports the compound was “well-tolerated” with “no psychologic, physiologic, or biochemical side effects observed” in the 6 subjects at the single 25 nmol/kg IV dose. No repeated-dose or chronic-use human safety data exists at any dose.
Community-reported practice (unverified)
Reported research-community practice — attributed to where it circulates, not to the trial above, and not independently verified by Prof. Peptide — is 100–200 mcg subcutaneously at bedtime, with some protocols reported at 250–500 mcg, and a similar 100–250 mcg range reported intranasally. This diverges from the cited study in route (subcutaneous or intranasal versus the study’s intravenous infusion), in schedule (repeated bedtime dosing versus the study’s single acute dose), and in magnitude — the cited study’s ~21 mcg/kg figure works out to roughly 1.5 mg for a 70 kg adult, several times higher than the commonly reported subcutaneous range, though the two are not directly comparable given the different routes. A commonly reported cycle is 5–7 days on with a break; continuous daily long-term use is uncommon in what is reported and has no safety data behind it at any dose.
The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.
How is DSIP administered?
DSIP is administered as a subcutaneous injection at bedtime (the most common route). Intranasal alternative also used. The 30–60 minutes before sleep window is typical. Combining with sedatives or alcohol carries a possible additive CNS-depressant effect. For SC technique, see the syringes and injection technique guide.
- Route. Subcutaneous injection at bedtime is the most common route. Intranasal also used.
- Time of day. 30–60 minutes before sleep. Some protocols use daytime dosing for the next-night effect.
- With or without food. Either is fine — DSIP can be absorbed orally (unusual for a peptide), but injection is preferred for research dosing.
- Site rotation. Sites are conventionally rotated each injection (abdomen, thigh, upper arm).
- Missed dose. Reported practice skips and resumes at the next scheduled dose. The convention is not to double-dose.
- Conflicts with sedatives. Combining with sedatives, benzodiazepines or alcohol carries a possible additive CNS-depressant effect.
- Cycle structure. 5–7 days on, with breaks. Continuous daily long-term use is not supported by the available safety data.
Timing context. DSIP's most distinctive timing feature is the “next-night effect” reported in some research — daytime dosing producing improved sleep on subsequent nights, suggesting downstream regulatory rather than acute sedative action. The plasma half-life is short, but biological effects persist far longer. The bedtime protocol is convention; the next-night protocol is an alternative used in specific research contexts.
| Aspect | Reported |
|---|---|
| Frequency | Once daily; a 5–7 day cycle is reported community practice, not derived from a trial or label; Prof. Peptide has not independently verified it. |
| Best time of day | Bedtime (30–60 min before sleep) or daytime for next-night effect |
| Food | No fasting required |
| Route choice | Subcutaneous most common; intranasal alternative; oral absorbed (unusual for peptide) |
| Half-life | Short plasma half-life; biological effects persist far longer |
| Steady-state | Per-dose effect on sleep; cumulative anti-stress effects build over days-weeks |
Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. DSIP research vials are typically 5 mg. Because doses are small (50–200 mcg), 2 mL reconstitution is common — it gives clean whole-number units across the typical dose range. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 5 mg vial.
| BAC water | Concentration | 50 mcg dose | 100 mcg dose | 200 mcg dose | 300 mcg dose |
|---|---|---|---|---|---|
| 1 mL | 5 mg/mL | 1 unit | 2 units | 4 units | 6 units |
| 2 mL | 2.5 mg/mL | 2 units | 4 units | 8 units | 12 units |
| 3 mL | 1.67 mg/mL | 3 units | 6 units | 12 units | 18 units |
Units vs mcg. At a 5 mg vial, each unit drawn delivers 50 mcg of DSIP at 1 mL reconstitution, 25 mcg at 2 mL, and 16.7 mcg at 3 mL. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.
What does DSIP stack well with?
DSIP's safer pairings are non-peptide supplements (magnesium glycinate, L-Theanine — additive sleep support). Selank's anxiolytic effect may complement DSIP's stress-reduction. BPC-157 is compatible without direct interaction. The important non-stacking is sedatives, benzodiazepines, and alcohol — additive CNS depression risk.
- Magnesium glycinate. Additive sleep support; common safe combination.
- L-Theanine. Additive calming effect; safe combination.
- BPC-157. BPC-157 — different mechanism (healing/gut). No direct interaction.
- Selank. Selank — anxiolytic effect may complement DSIP's stress-reduction; no published interaction data.
- Conflicts: sedatives, benzodiazepines, alcohol. Possible additive CNS depression risk.
What are the side effects of DSIP?
DSIP has the weakest safety database of any peptide on Prof. Peptide. The FDA has explicitly flagged DSIP for potential immunogenicity in compounded preparations — meaning the body may mount a potentially serious immune response. Most published safety data comes from short-term animal studies and limited human research from the 1980s–1990s. Long-term effects are unknown. The absence of harm signals in limited research is NOT the same as proven long-term safety.
Common (most users)
- Daytime drowsiness. If dose is too high or mistimed.
- Mild headache or dizziness.
- Mild gastrointestinal discomfort, nausea. Occasional.
Less common (moderate)
- Hormonal fluctuations. DSIP affects LH, GH, somatostatin.
- Mild fluid retention.
- Mild fatigue or grogginess.
Serious (rare)
- Potential immunogenicity. FDA has flagged DSIP for risk of immune-mediated adverse reactions in compounded preparations.
- Long-term safety unknown. Most research is short-term animal studies.
- No published cases of severe adverse events. Though clinical experience is very limited.
DSIP has the weakest safety database of any peptide on Prof. Peptide. The FDA has explicitly flagged DSIP for potential immunogenicity in compounded preparations — meaning the body may mount an immune response that is potentially serious. Most published safety data comes from short-term animal studies and limited human research from the 1980s–1990s. Long-term effects are unknown. The 2001 European Journal of Anaesthesiology editorial described DSIP as “incredibly safe” based on the lack of acute toxicity in animal studies, but the absence of harm signals in limited research is not the same as proven long-term safety.
Does DSIP interact with other drugs?
DSIP's relevant interactions are with sedatives and benzodiazepines (possible additive CNS depression — combine with caution), alcohol (limited data, avoid combination), and hormonal medications (DSIP affects LH, GH, somatostatin — theoretical interaction with hormone replacement or fertility treatments). No major drug-drug interactions formally documented (largely because DSIP has limited modern clinical study).
- Sedatives and benzodiazepines. Possible additive CNS depression; combine with caution.
- Alcohol. Limited data; avoid combination given DSIP's CNS effects.
- Hormonal medications. DSIP affects LH, GH, somatostatin; theoretical interaction with hormone replacement or fertility treatments.
- No major drug-drug interactions formally documented (largely because DSIP has limited modern clinical study).
How should DSIP be stored?
- Lyophilized (powder) form: Store at -20°C for long-term storage; refrigerate at 2–8°C for short-term.
- Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade DSIP remains stable — this page does not state a duration as fact.
- Reconstitution uses bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
- The reconstituted solution is never frozen.
- DSIP is stored protected from light, in the original carton.
- A solution that is cloudy, discolored, or contains particles is discarded.
What are the limitations of DSIP research?
DSIP has one of the weakest evidence bases of any peptide on Prof. Peptide. NOT FDA-approved. FDA has explicitly flagged DSIP-containing compounded drugs for potential immunogenicity risk. Most research is from the 1970s–1990s with limited modern human clinical trials. Mechanism remains incompletely characterized after 50 years. Conflicting evidence on sleep effects — some studies failed to replicate original findings. Described as 'a fascinating but unfinished chapter in peptide research'.
DSIP has one of the weakest evidence bases of any peptide on Prof. Peptide. It is NOT FDA-approved for any human use. The FDA has explicitly flagged DSIP-containing compounded drugs for potential immunogenicity risk, meaning the body may perceive DSIP as a threat and mount a potentially serious immune response.
Most published research on DSIP comes from the 1970s–1990s, with limited modern human clinical trials. The mechanism of action remains incompletely characterized after 50 years of research. Some studies failed to replicate the original sleep-promoting findings. Modern reviewers describe DSIP as “a fascinating but unfinished chapter in peptide research” rather than a proven sleep therapy.
Conflicting evidence exists on DSIP's involvement in sleep regulation — some studies link it to slow-wave sleep promotion and REM suppression, others show no consistent sleep effects. The original “delta sleep-inducing” name reflects the discovery context, not validated clinical action.
Research-grade DSIP material is sold for laboratory use only. Purity and potency vary by vendor — and given the FDA's immunogenicity flag, third-party testing is especially important for any DSIP product.
The World Anti-Doping Agency does not currently include DSIP on the prohibited list, but the peptide's effects on GH and LH could theoretically have sport-related implications.
DSIP FAQ
Does DSIP actually induce sleep?
The original name reflects the 1977 discovery context — DSIP was isolated from rabbits in deep delta-wave sleep. Modern research describes DSIP more accurately as a sleep-modulating substance that improves disturbed sleep with minimal effect on healthy sleepers. It is NOT a direct sedative like a benzodiazepine. Some research even shows DSIP given during the day produces improved sleep on the next night — suggesting downstream regulatory effects, not acute sedation.
Is DSIP safe?
Long-term safety is not established. Available animal studies show low acute toxicity, but the FDA has explicitly flagged DSIP for potential immunogenicity — meaning the body may mount an immune response. Most modern human clinical experience is anecdotal and limited. DSIP has the weakest safety database of any peptide on Prof. Peptide.
How does DSIP differ from melatonin?
Mechanism completely different. Melatonin regulates sleep timing through circadian receptors. DSIP appears to affect sleep depth and recovery quality, with possible anti-stress and hormonal effects. Melatonin has decades of human safety data; DSIP has very limited modern human research. Melatonin is generally a safer first choice for sleep difficulty.
Why does DSIP appear in breast milk?
DSIP-like substances are present in human breast milk at higher concentrations than in plasma. Some researchers have hypothesized this contributes to post-feeding sleep tendencies in newborns, though this remains unproven.
What's the right dose?
There is no standardized clinical dose. Original IV human studies used 25 nmol/kg (~21 mcg/kg). Modern subcutaneous protocols typically use 100–200 mcg per dose, but this is derived from biohacker community reports rather than clinical trials. The reported practice is to begin at the low end (50–100 mcg) and titrate up only if needed.
Should I take DSIP daily?
Continuous daily long-term use lacks safety data. Most protocols use 5–7 days on with breaks. Given the FDA's immunogenicity flag and limited human clinical experience, conservative cycling is the prudent approach.
How does DSIP compare to other sleep peptides?
DSIP is the only widely-discussed 'sleep peptide' with substantial historical research. Other sleep-related peptides (orexin antagonists, melatonin analogs) work through different mechanisms and have stronger clinical evidence. For severe sleep disturbance, DSIP is not a first-line option in any published guidance — established treatments with FDA approval and known safety profiles are safer choices.
Where can I buy DSIP?
DSIP is not FDA-approved and is sold by specialty research peptide vendors. Quality varies and the FDA has flagged immunogenicity concerns — third-party testing is especially important. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .
References
- Pollard BJ, Pomfrett CJ. Delta sleep-inducing peptide. Eur J Anaesthesiol. 2001;18(7):419-22. https://pubmed.ncbi.nlm.nih.gov/11437870/
- Graf MV, Kastin AJ, Coy DH, Fischman AJ. Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. Neuroendocrinology. 1985;41(5):353-6. https://pubmed.ncbi.nlm.nih.gov/2995861/
- Wikipedia. Delta-sleep-inducing peptide. https://en.wikipedia.org/wiki/Delta-sleep-inducing_peptide
- Schneider-Helmert D. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341-5. https://pubmed.ncbi.nlm.nih.gov/6895513/
- Khvatova EM, Belousova ID, Sazanova EI, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173. https://www.mdpi.com/1420-3049/26/17/5173
- Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. https://pubmed.ncbi.nlm.nih.gov/6548970/
Published Studies
Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.
Schoenenberger GA, Monnier M.
The foundational paper that isolated and characterized DSIP from rabbit cerebral venous blood. Researchers demonstrated that the nonapeptide induced increases in delta-wave EEG activity when administered to rabbits, establishing both the compound and its name.
Graf MV, Kastin AJ.
A comprehensive review synthesizing the first decade of DSIP research. The paper covers DSIP's effects on sleep, hormone release, stress response, and thermoregulation across multiple species.
Kovalzon VM, Strekalova TV.
A critical review examining why DSIP remains incompletely understood despite decades of research. The authors discuss the lack of a definitively identified receptor, the inconsistency of sleep findings, and the broad range of reported effects.
Susić V, Masirevic G, Totic S.
A classic experimental study examining DSIP's effects on sleep architecture in cats using EEG recording. The researchers documented significant increases in slow-wave sleep and reduced sleep latency after DSIP administration.
Graf MV, Kastin AJ.
A follow-up review to the 1984 paper, summarizing the second wave of DSIP research and proposing refinements to the understanding of its mechanism.
In the News
We may earn commissions from peptide vendor affiliate links.
Have a question about DSIP? Send us an email